Calida Therapeutics S.A.S.

https://www.calidatx.com

Calida Therapeutics is a preclinical stage biotechnology company developing monoclonal antibodies to treat and prevent thrombo-inflammatory disorders. Calida aims to become a leader in the new field of thrombo-inflammatory disorders which occur in a broad range of indications, from cardiovascular diseases to the complications of autoimmune diseases. Its novel approach aims to disrupt the molecular link between thrombosis and inflammation by preventing the crosstalk between platelets and myeloid cells, thus abolishing the chain reaction of these two phenomena leading to tissue damage and life-threatening events. The company is conducting additional in vivo proofs of concept to select a lead candidate. Calida’s approach is based on more than 20 years of research conducted in the Cleveland (Ohio, USA) academic ecosystem, by leading researchers. Calida was co-founded in December 2022 by Dr. Daniel Simon, MD, PhD, Dr. Edward Plow, PhD, and Dr. Yunmei Wang, PhD, together with the venture capital funds BioMotiv and AdBio partners. Based in Paris, France, the company has raised €2M ($2.17M) in seed funding from AdBio partners. *

	Start	2022-12-23 established
	Industry	therapeutic antibody
	Industry 2	MAb
	Person	Bertholet, Clément (Calida Therapeutics 202304– CEO + Operating Partner at AdBio Partners before Thabor Therapeutics)

	Region	Paris
	Country	France
	Street	4 rue Thenard
	City	75005 Paris
		Address record changed: 2023-04-08

Basic data	Employees	n. a.

		* Document for »About Section«: Calida Therapeutics S.A.S.. (4/6/23). "Press Release: French Biotech Calida Therapeutics Launches with Seed Funding, Leveraging US Academic Research in Thrombo-inflammatory Disorders". Paris.

		Record changed: 2023-07-10

Picture BIO.NRW Greener Manufacutring Show 2023 Köln 650x200px

More documents for Calida Therapeutics S.A.S.

[1] Calida Therapeutics S.A.S.. (4/6/23). "Press Release: French Biotech Calida Therapeutics Launches with Seed Funding, Leveraging US Academic Research in Thrombo-inflammatory Disorders". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)